Status:
UNKNOWN
Revitalization of Damaged Skin Due to Chronic Skin Diseases
Lead Sponsor:
Ace Cells Lab Limited
Conditions:
Chronic Eczema
Psoriasis
Eligibility:
All Genders
Phase:
EARLY_PHASE1
Brief Summary
Chronic skin disease lead to skin damage and disfiguring to the patient skin. Sometimes, achieving normal skin is not possible by the normal traditional treatment, this study is focusing on use of ACE...
Detailed Description
Psoriasis is a chronic, immune mediated (type 2 and type 17) chronic skin disease. The production of the immune proteins that leads to continuous inflammatory mediated process. The result of chronic i...
Eligibility Criteria
Inclusion
- Chronic skin condition lasts for more than 1 year.
- tried traditional treatment with limited or without effect.
- not on steroids for at least 6 weeks.
Exclusion
- patients on steroid.
- patients intolerable to protein or allergic to proteins
- during pregnancy or lactation
Key Trial Info
Start Date :
May 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2019
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT03485560
Start Date
May 1 2018
End Date
January 1 2019
Last Update
April 2 2018
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
ACE cells Lab Europe Doo
Belgrade, Serbia, 11000
2
ACE Cells Lab Limited
Nottingham, Nottinghamshire, United Kingdom, NG90 6BH